Simulations Plus (SLP) Rating Increased to Buy at BidaskClub

BidaskClub upgraded shares of Simulations Plus (NASDAQ:SLP) from a hold rating to a buy rating in a report published on Tuesday morning.

SLP has been the subject of a number of other research reports. Zacks Investment Research raised Simulations Plus from a hold rating to a buy rating and set a $20.00 target price for the company in a report on Saturday, July 21st. ValuEngine downgraded Simulations Plus from a strong-buy rating to a buy rating in a report on Wednesday, July 11th.

Shares of Simulations Plus stock opened at $20.12 on Tuesday. Simulations Plus has a 1 year low of $14.25 and a 1 year high of $23.95. The firm has a market cap of $357.20 million, a price-to-earnings ratio of 51.42 and a beta of -0.81.

In other news, Director Walter S. Woltosz sold 18,500 shares of Simulations Plus stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $19.92, for a total transaction of $368,520.00. Following the completion of the sale, the director now owns 5,417,908 shares of the company’s stock, valued at $107,924,727.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 55,500 shares of company stock valued at $1,073,185 in the last three months. Insiders own 33.45% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of SLP. MetLife Investment Advisors LLC acquired a new position in Simulations Plus in the second quarter valued at about $129,000. Bank of Montreal Can acquired a new position in Simulations Plus in the second quarter valued at about $186,000. TIAA FSB acquired a new position in Simulations Plus in the second quarter valued at about $225,000. Acadian Asset Management LLC acquired a new position in Simulations Plus in the second quarter valued at about $233,000. Finally, Rhumbline Advisers acquired a new position in Simulations Plus in the second quarter valued at about $246,000. 35.70% of the stock is owned by institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.

See Also: Technical Analysis

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply